SVB Leerink Upgrades Pacira Pharmaceuticals (PCRX) to Outperform
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $23.18 --0%
Rating Summary:
11 Buy, 16 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 9
Rating Summary:
11 Buy, 16 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 9
Join SI Premium – FREE
SVB Leerink analyst Ami Fadia upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Market Perform to Outperform with a price target of $44.00 (from $46.00).
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $32.52 yesterday.
You May Also Be Interested In
- Wells Fargo Upgrades FOX Corp. (FOXA) to Overweight
- Aya Gold & Silver Inc (AYA:CN) (MYAGF) PT Raised to Cdn$41 at BMO Capital
- Ascendis Pharma (ASND) PT Raised to $290 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
